ReviewJACS Au2021
Membrane-Disrupting Molecules as Therapeutic Agents: A Cautionary Note.
Review in JACS Au, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Light-controlled inhibition of Gram-positive bacteria by photoswitchable amphiphilic lipids (PALs).RSC medicinal chemistry · 2026Article
- Bioactive Aromatic Plant Extracts Modulate Metabolism and Inflammation in HeLa Cells.Molecules (Basel, Switzerland) · 2025Article
- The Perspectives of Combining Antibiotics with Saponins-Herbal Excipients.Molecules (Basel, Switzerland) · 2025Review
- Bivalent single-domain antibodies show potent mpox virus neutralization through M1R antigen.Communications biology · 2025Article
- Bisphosphonium Amphiphiles Yield Insights into Gram-Negative Bacterial Disinfectant Resistance and Cell Membrane Interactions.ACS omega · 2025Article
- Fabrication of a Lipopolysaccharide-Targeting Peptide-Based Colloid for Alleviating Carbapenem-Resistant Enterobacteriaceae-Induced Cutaneous Infection.Advanced healthcare materials · 2025Article
- Antimicrobial and ADME properties of methoxylated, methylated and nitrated 2-hydroxynaphthalene-1 carboxanilides.ADMET & DMPK · 2025Article
- Erythronecroptosis: an overview of necroptosis or programmed necrosis in red blood cells.Molecular and cellular biochemistry · 2024Review
- Mechanisms of Triton X-100 reducing the AgWorld journal of microbiology & biotechnology · 2024Article
- Drug Design: Do Not Forget the Supramolecular Factor.Biochemistry · 2024Review
- An Endosomal Escape Trojan Horse Platform to Improve Cytosolic Delivery of Nucleic Acids.ACS nano · 2024Article
- Unraveling lipid and inflammation interplay in cancer, aging and infection for novel theranostic approaches.Frontiers in immunology · 2024Review
- Invasion by exogenous RNA: cellular defense strategies and implications for RNA inference.Marine life science & technology · 2023Review
- Recent developments in membrane targeting antifungal agents to mitigate antifungal resistance.RSC medicinal chemistry · 2023Review
- Core-Shell DNA-Cholesterol Nanoparticles Exert Lysosomolytic Activity in African Trypanosomes.Chembiochem : a European journal of chemical biology · 2022Article
- Mansonone G and its derivatives exhibit membrane permeabilizing activities against bacteria.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mechanistic studies have shown that aggregates of a common membrane disrupting molecule, Triton X-100, destroy the integrity of cholesterol-rich phospholipid bilayers via a catastrophic rupture process. In sharp contrast, attack on such membranes by monomers of Triton X-100 destroys their integrity through mild leakage events. This discovery of duplicity in the destruction of membrane integrity by a membrane-disrupting molecule has led to the design of derivatives of Amphotericin B that exhibit a lower tendency to aggregate and antifungal and hemolytic activities that are well-separated. An animal study with one such derivative has shown that its efficacy is similar to that of Amphotericin B but with substantially reduced toxicity. A related
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.